← stocks-llm Find companies like QTRX →

QUANTERIX CORP (QTRX)

Health Care · Life sciences research instrumentation and in vitro diagnostics · NASDAQ

Quanterix develops ultra-sensitive protein detection and spatial tissue analysis platforms for biomarker discovery and early disease diagnostics, with recent FDA breakthrough designation for an Alzheimer's blood test.

View SEC filings Website Yahoo Finance Find companies like QTRX → Ask about QTRX →

What QUANTERIX CORP does

Quanterix is a life sciences company that develops ultra-sensitive translational research and spatial biology instruments, consumables, and services for biomarker discovery and diagnostics. The company operates two core platforms: Simoa, a proprietary digital detection technology that identifies protein biomarkers at ultra-low concentrations in blood and other fluids; and Spatial Biology platforms (through acquired Akoya) that enable multi-plex analysis of biomarkers in tissue samples at single-cell resolution. Quanterix also provides contract research services and clinical laboratory testing services, including Laboratory Developed Tests for applications in neurology, oncology, immunology, and inflammation.

Themes: ["Biomarker detection and discovery","Translational research instrumentation","Spatial biology / tissue analysis","Early disease detection and diagnostics","Neurology / Alzheimer's disease diagnostics","Oncology research and diagnostics","Immunology and inflammation research","Clinical laboratory testing services"]

Fundamentals

Ask why QTRX looks like this →

Key risks (from latest filing)

["Rapid competitive environment with changing market dynamics; limited ability to predict emerging risks and competitive threats in translational research and diagnostics markets","Dependency on FDA regulatory approval and reimbursement decisions (e.g., LucentAD pricing and coverage); delays or unfavorable outcomes could impact diagnostic revenue and adoption","High operating expenses and negative net margins (-71.86%) with inability to achieve profitability despite 6.85% revenue growth; significant intangible asset impairment ($19.8M in Q1 2026) indicates valuation challenges from recent acquisitions (Akoya, Emission)"]

See QTRX's biggest risks from its latest 10-Q →

Competitors & peers

Not quite? Describe exactly what you want →

Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.

Last updated 2026-07-09.

Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.